| Dr Steven Michael Kelly, MD | |
|
1551 Renaissance Towne Dr, Suite 310, Bountiful, UT 84010-7667 | |
| (801) 295-5581 | |
| (801) 295-9253 |
| Full Name | Dr Steven Michael Kelly |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology - Pediatric Otolaryngology |
| Location | 1551 Renaissance Towne Dr, Bountiful, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1841348240 | NPI | - | NPPES |
| 110583300 | Medicaid | WY | |
| 003084400 | Medicaid | ID |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YP0228X | Otolaryngology - Pediatric Otolaryngology | 182660-1205 (Utah) | Primary |
| Entity Name | Ihc Health Services Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1629260880 PECOS PAC ID: 1850209420 Enrollment ID: O20031105000079 |
News Archive
I know, I know, Democracy's dead, the Union's crumbling and "big guvment" is knocking down your door to deliver forced proctology exams — without latex gloves. ... Well, my friends, get a grip. What really happened, finally, is a House elected by a majority decided to act in the majority's interest. What happened is the start of an effort to fix a problem that sooner or later touches everyone.
A specialist in men's health suggests that warning overweight men about the consequences of fat on their sex lives may help them shed their kilos where other strategies have failed.
Dietary information from three large, well-known heart disease studies suggests drinking one or more cups of caffeinated coffee may reduce heart failure risk, according to research published today in Circulation: Heart Failure, an American Heart Association journal.
A cardiovascular research team from Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women's Hospital (BWH), led by BIDMC Principal Investigator Saumya Das, MD, PhD, has been awarded a $4 million Common Fund grant from the National Institutes of Health (NIH) as part of a newly formed program on Extracellular RNA Communication.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
› Verified 6 days ago
| Entity Name | University Of Utah Pediatric Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487018974 PECOS PAC ID: 0547552473 Enrollment ID: O20160713000371 |
News Archive
I know, I know, Democracy's dead, the Union's crumbling and "big guvment" is knocking down your door to deliver forced proctology exams — without latex gloves. ... Well, my friends, get a grip. What really happened, finally, is a House elected by a majority decided to act in the majority's interest. What happened is the start of an effort to fix a problem that sooner or later touches everyone.
A specialist in men's health suggests that warning overweight men about the consequences of fat on their sex lives may help them shed their kilos where other strategies have failed.
Dietary information from three large, well-known heart disease studies suggests drinking one or more cups of caffeinated coffee may reduce heart failure risk, according to research published today in Circulation: Heart Failure, an American Heart Association journal.
A cardiovascular research team from Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women's Hospital (BWH), led by BIDMC Principal Investigator Saumya Das, MD, PhD, has been awarded a $4 million Common Fund grant from the National Institutes of Health (NIH) as part of a newly formed program on Extracellular RNA Communication.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Steven Michael Kelly, MD 2255 N 1700 W, Suite 200, Layton, UT 84041-1140 Ph: (801) 776-2180 | Dr Steven Michael Kelly, MD 1551 Renaissance Towne Dr, Suite 310, Bountiful, UT 84010-7667 Ph: (801) 295-5581 |
News Archive
I know, I know, Democracy's dead, the Union's crumbling and "big guvment" is knocking down your door to deliver forced proctology exams — without latex gloves. ... Well, my friends, get a grip. What really happened, finally, is a House elected by a majority decided to act in the majority's interest. What happened is the start of an effort to fix a problem that sooner or later touches everyone.
A specialist in men's health suggests that warning overweight men about the consequences of fat on their sex lives may help them shed their kilos where other strategies have failed.
Dietary information from three large, well-known heart disease studies suggests drinking one or more cups of caffeinated coffee may reduce heart failure risk, according to research published today in Circulation: Heart Failure, an American Heart Association journal.
A cardiovascular research team from Beth Israel Deaconess Medical Center (BIDMC) and Brigham and Women's Hospital (BWH), led by BIDMC Principal Investigator Saumya Das, MD, PhD, has been awarded a $4 million Common Fund grant from the National Institutes of Health (NIH) as part of a newly formed program on Extracellular RNA Communication.
Amgen (Nasdaq: AMGN) today announced detailed results from the Phase 3 '181' trial evaluating Vectibix((R)) (panitumumab) in combination with FOLFIRI (an irinotecan based chemotherapy), as a second-line treatment for metastatic colorectal cancer (mCRC). In this trial, Vectibix significantly improved progression-free survival (PFS) in patients with KRAS wild-type mCRC.
› Verified 6 days ago
Derek L Vanhille, MD Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1551 Renaissance Towne Dr Ste 310, Bountiful, UT 84010 Phone: 801-295-5581 Fax: 801-295-9253 | |
Curt Robert Stock, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1551 Renaissance Towne Dr, Suite 310, Bountiful, UT 84010 Phone: 801-295-5581 Fax: 801-295-9253 | |
Dr. Joshua Brian Bradshaw, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1551 Renaissance Towne Dr Ste 310, Bountiful, UT 84010 Phone: 801-295-5581 Fax: 801-295-9253 | |
Dr. Demetrios Gregory Skedros, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1551 Renaissance Towne Dr, Suite 310, Bountiful, UT 84010 Phone: 801-295-5581 Fax: 801-295-9253 |